Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase 1 Randomized, Double-blind, Placebo-controlled, Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease

Authors not listed

Kyowa Kirin Co., Ltd. · 2017

Abstract

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of KHK6640, given as a repeated dose in Japanese patients with Mild to Moderate Alzheimer's Disease.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-08 MST

Cite this

APA
Anonymous. (2017). A Phase 1 Randomized, Double-blind, Placebo-controlled, Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease. <em>Kyowa Kirin Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT03093519
Vancouver
Anonymous. A Phase 1 Randomized, Double-blind, Placebo-controlled, Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease. Kyowa Kirin Co., Ltd.. 2017.
BibTeX
@misc{anon2017APhase, title = {A Phase 1 Randomized, Double-blind, Placebo-controlled, Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease}, author = {Anonymous}, journal = {Kyowa Kirin Co., Ltd.}, year = {2017}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings